Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

Dr Bradstreet at the Treating Autism Conference 9th September 2012

Discussion in 'GcMAF' started by Trevor Banks, Sep 26, 2012.

  1. Trevor Banks

    Trevor Banks

    Talking at the Treating Autism Conference 2012 (, Dr Bradstreet explains how he made the connection between HIV patients, GcMAF and autism, and how he uses GcMAF from First Immune . He has checked the process and quality control and describes their laboratory as a boutique laboratory. He satisfies himself as to the quality, sterility and activity of the GcMAF and this has also confirmed by Prof Ruggerio in Italy. His medical paper is currently under peer review and will be published as soon as this process is completed. This describes how the presence of nagalase creates a reduction of naturally occurring GcMAF and observed reduction of nagalase from injectable GcMAF. He then goes on to describe the levels of success he is seeing in the treatment of autism using First Immune GcMAF

    Extract and full version are available to view here:

    Google gcmaf dot eu Dr Bradstreet at the Treating Autism Conference 9th September 2012

See more popular forum discussions.

Share This Page